Using a fragment of the murine flt3 ligand as a probe, we have succeeded in cloning a human flt3 ligand from a human T-cell XgtlO cDNA library. The human and murine ligands are 72% identical at the amino acid level. Analysis of multiple cDNA clones shows that alternative splicing of the human fh3 mRNA can occur at a number of positions. A recombinant soluble form of the human flt3 ligand stimulates the proliferation and colony formation of a subpopulation of hu-NUMBER OF LIGANDS for tyrosine kinase receptors play a role in regulating the proliferation and differentiation of cells in the hematopoietic system. These include colony-stimulating factor 1 (CSF-l), which regulates the survival, proliferation, and differentiation of mononuclear phagocytic cells,' and Steel factor (SLF) (also known as mast cell growth factor, stem cell factor, or kit ligand), which affects the proliferation of both myeloid and lymphoid cells.' Several years ago a new tyrosine kinase receptor was cloned, alternately named as flt3 or flk-2, that was structurally related to the CSF-1 and SLF receptor^.^.^ This receptor was described by one group as being selectively expressed on hematopoietic stem and progenitor cell-enriched fetal liver popul a t i o n~.~ We have recently cloned a novel hematopoietic growth factor from a murine T-cell line that is a ligand for the flt3/flk-2 tyrosine kinase receptor.' This growth factor, which we refer to as a flt3 ligand, stimulates the proliferation of hematopoietic progenitor cells isolated from mouse fetal liver or adult mouse bone marrow (BM).5 In addition, the murine factor was functionally active on human CD34+ BM cells that are enriched for hematopoietic stem c e k 5
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The flt3 ligand is similar in size and structure to SLF and CSF-1 in that all three proteins are type I transmembrane proteins with short cytoplasmic domains; four cysteine residues appear to be conserved in the extracellular domains of all three of these growth factors. A fragment of the murine flt3 ligand cDNA was used as a probe to screen a human Tcell cDNA library for a human flt3 ligand cDNA. We now report the cloning of a human flt3 ligand, which is similar in structure to the murine protein and shares 72% amino acid identity. A soluble form of the human flt3 ligand stimulates the proliferation and colony formation of a subpopulation of human BM cells that are CD34+ and are enriched for hematopoietic progenitor cells. 0.1% sodium dodecyl sulfate (SDS) for 1 hour, then 1 X SSC/O.l% SDS for 1 hour, and finally 0.5X SSC/O.l% SDS for 1 hour. DNA from positive phage plaques was extracted, inserts were amplified by PCR using oligonucleotides specific for the phage arms, and the DNA was sequenced. A total of six cDNAs were isolated from this library (after screening 480,000 phage clones) that corresponded to the human flt3 ligand sequence. Two clones appeared to be identical by restriction digestion, so only five clones were sequenced. We were also able to isolate human ft13 ligand cDNA clones using a probe derived from the murine ft13 ligand 5H cDNA clone (data not shown).
A MATERIALS AND METHODS

Cloning
Construction of a splicing variant of the human flt3 ligand. A 179-bp deletion seen in the clone 14 flt3 ligand cDNA (Fig 1) was transferred into the wild-type clone 9 flt3 ligand cDNA as follows. The wild-type clone 9 cDNA (in the pBluescript [Stratagene, La Jolla, CA] vector) was cut with EcoNI, and a 319-bp fragment containing the 179-bp segment was removed (bp 478 to 796 in Fig  2) . Similarly, the clone 14 flt3 ligand cDNA (in the pBluescript vector) was also cut with EcoNI and a 140-bp fragment that spans the desired 179-bp deletion was isolated. The 140-bp EcoM fragment isolated from clone 14 was then ligated into the clone 9 cDNA, and a recombinant clone was identified by restriction digest. The recombinant clone was sequenced to confirm the endpoints of the deletion as well as the orientation of the insert. Both the clone 9/A179 flt3 ligand as well as the wild-type clone 9 flt3 ligand cDNAs were then transferred into the pDC302 expression vecto? for expression of the protein in CV-l/EBNA cells.
DNA andprotein sequence analysis. DNA and protein sequence analysis was performed using the GCG software package (University of Wisconsin, Madison).' The signal peptide was identified using the algorithm of von Heijne? and the transmembrane domain was identified using the algorithm of Eisenberg et al? DNA sequencing was performed by primer walking using the AB1 Taq DyeDeoxy Terminator Cycle Sequencing kit on an automated DNA sequencer (model 373A; Applied Biosystems, Foster City, CA). Both strands of each of the cDNA clones were sequenced in their entirety. Northern blot analysis offlt3 ligand expression. Human tissue Northern blots were purchased from Clontech (Palo Alto, CA); each lane contains approximately 2 pg of poly A+ mRNA. The blots were hybridized overnight at 55°C with a polymerase chain reaction (PCR) generated fragment of the human flt3 ligand containing nucleotides 161 through 574 (Fig 2) that had been random-primed. The blot was then washed to 2X SSC/O.l% SDS for 1 hour, then 1 X SSC/0.1% SDS for 1 hour, and finally 0.5X SSC/O.l% SDS for 1 hour, then put to film. The blots were later probed without being stripped with a @actin probe as a loading control for the various mRNAs according to the manufacturer's directions.
Activity of humanJt3 ligand on human CD34' BM cells and cells expressing the murine fit3 receptor. Recombinant soluble human flt3 ligand was produced in yeast essentially as described before for the murine ligand.' The recombinant human ligand contains amino acids 27 through 179 of the extracellular domain of the protein (see Fig 2) and has an octapeptide sequence (FLAG) at its N-terminus that is used to affinity purify the protein.' Soluble yeast-derived flt3 ligand was used in a ['HI-thymidine proliferation assay on human CD34' BM cells and also in a [%-thymidine proliferation assay on interleukin-3 (IL-3)-dependent BAF/B03 cells transfected with the murine flt3 receptor as described previously.'
Hematopoietic colony assay. Human BM or cord blood-derived CD34' cells were isolated as described previously.' Approximately 90% of the enriched cell population was CD34+ (data not shown). Cells were plated in 0.5 mL of methylcellulose medidwell (methocult H4230; Teny Fox Laboratory, Vancouver, Canada) in 24-well plates (600 cells/well for BM and 800 ceIls/well for cord blood). Cytokines were added at the following concentrations: 2 U/mL erythropoietin (EPO) (Terry Fox Laboratory), 10 ng/mL IL-3,20 ng/mL granulocytemacrophage colony-stimulating factor (GM-CSF), 250 ng/mL SLF, and 20 ng/mL Pixy 321, which is a GM-CSF-IL-3 fusion protein."' flt3 ligand was added at 100 ng/mL alone and in combination with other factors. The plates were incubated in a 37"C, 7% 02, 6.5% CO2 incubator and total colony numbers were counted on day 14.
Binding assays. CV-1EBNA cells were transfected with various flt3 ligand cDNA expression constructs and assayed 2 days later for their capacity to bind a flt3-Fc fusion protein (a soluble version of the flt3 receptor) using methods described previously.'
RESULTS
Cloning of the humanjt3 ligand. The murine flt3 ligand was cloned from a murine T-cell line5 and is expressed on a number of murine T-cell lines (S.D.L., unpublished data). Therefore, we decided to screen a random-primed cDNA library in AgtlO constructed from human clone 22 T-cell mRNA6 to isolate human flt3 ligand clones. Five human flt3 ligand cDNA clones were isolated (Fig 1) by screening this library with a 413-bp Ple I fragment from the extracellular domain of the murine flt3 ligand. Of the five cDNA clones isolated, two clones (nos. 9 and 8) encoded full-length proteins corresponding to the murine flt3 ligand sequence, and one clone (no. 22) contained a partial flt3 ligand sequence. Two other clones, nos. 14 and 24, contained flt3 ligand clones that have undergone alternate splicing that disrupts the reading frame as described below. The sequence shown in Fig 2 is a composite that represents clone no. 9, with additional 5' and 3' noncoding regions from clone no. 8.
Analysis of the sequence of a composite human flt3 ligand cDNA (Fig 2) showed an open reading frame of 705 bp surrounded by 83 bp of 5' noncoding sequence and 321 bp of 3' noncoding sequence (Fig 2) . There were no in-frame stop codons upstream of what we are designating the initiator methionine. The open reading frame encodes a type I transmembrane protein of 235 amino acids. Analysis of the amino acid sequence indicates that the protein has an N-terminal signal peptide of 26 amino acids, followed by a 156-amino acid extracellular domain, a 23-amino acid transmembrane domain, and a 30-amino acid cytoplasmic domain. There are two potential sites for N-linked glycosylation in the extracellular domain of the protein that are at the same positions as seen in the murine protein. The mouse and human flt3 ligand sequences are 72% identical at the amino acid level (Fig 3) and 76% identical at the nucleotide level in the coding region (data not shown). This level of homology is consistent with results obtained by Southern blot analysis in which hybridization of the murine ligand to human genomic DNA could not be detected after washing at moderate stringency (OSX SSC at 63"C).'The 3' noncoding region of clone no. 8 ended in a poly A tail; 15 bp upstream of the tail was a sequence similar to a consensus poly A addition signal (TATAAA as compared with the consensus AATAAA) that likely directs polyadenylation of the message. The TATAAA sequence was found in both clones no. 8 and 24 (data not shown). Polyadenylation signals that are not AATAAA occur relatively infrequently,"." and this uncommon hexanucleotide sequence is used in hepadnaviruses to signal polyadenylation.I3 Also seen in the 3' noncoding region is a sequence motif (bp 101 5 through IO 19; ATTTA) that may be responsible for rapid turnover of the mRNA.'4.'s The coding regions of clones 8, 9, and 22-1 are identical except that clone 22-1 is truncated and ends approximately 13 amino acids before the termination codon. Clone 14 is unlikely to encode a biologically active protein as a result of the frame shift caused by the insertion of a 17-bp DNA segment in the middle of the signal peptide sequence (Fig  2) . The 30-bp deletion seen in the middle of the clone no. 14 sequence begins at the same nucleotide as the 139-bp deletion seen in clone no. 24. The 30 nucleotides deleted in clone no. 14 by this splicing would remove IO amino acids in the middle of the extracellular domain, but would preserve the reading frame. None of the four cysteines conserved between flt3 ligand, CSF-l, and SLF are in this segment, which is located between the third and fourth helices in our four helix bundle model of the flt3 ligand.s The point at which the 139-bp deletion in clone no. 24 ends is at exactly the same point at which the 179-bp deletion in clone no. 14 begins: moreover, this point is also the exact point of divergence between two murine flt3 ligand cDNAs isolated previously.s Thus, this splice junction has been retained in both species. Three of the clones (nos. 8, 14, and 22-1) have had 51 bp spliced out of their 3' noncoding region; all of these splices begin and end at the same nucleotides.
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Biologic activity of the human j7t3 ligand. Recombinant soluble flt3 ligand was produced in yeast (see Materials and Methods) and tested for its capacity to stimulate the proliferation of a subpopulation of human BM cells that are low density, soybean agglutinin-negative, and CD34'. This subpopulation of BM cells is considered to be enriched for hematopoietic stem cell and progenitor cells'' and proliferated in response to the human flt3 ligand (Fig 4) . The maximum response observed with these human cells (3.8-fold stimulation index) was similar to that seen with the murine flt3 ligand (data not shown). The CD34-fraction of the lowdensity, soybean agglutinin-negative cells did not proliferate in response to flt3 ligand (data not shown).
The capacity of human flt3 ligand to stimulate clonal colony formation from CD34' progenitor cells derived from BM and cord blood was also examined ( Table 1) . flt3 ligand alone induced significant colony formation from the BM progenitors but not the cord blood progenitors. The colonies observed were all of the granulocyte/monocyte (GM) type. The possibility that flt3 ligand could synergize with a number of cytokines known to induce colony formation was also tested. Synergy with flt3 ligand was observed in all three experiments with Pixy 321 and in two of the three experiments with IL-3 and GM-CSF. Colony size was also in- * Colony numbers for flt3 ligand + growth factor were greater than additive, P < .05.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Human flt3 ligand was also tested for its capacity to stimulate cells expressing the murine flt3 receptor. We have developed a cell line from IL-3-dependent murine BAF/B03 cells that expresses the murine flt3 receptor and responds to the murine flt3 ligand.' These cells also proliferated in response to the human ligand (Fig 5) . showing that the human factor is biologically active on both mouse and human cells.
Northern blot analvsis ofJlt3 ligand expression. Expression of the flt3 ligand in various organs was examined by probing human tissue Northern blots with a probe generated by PCR from the middle of the coding region of the human ligand (see Materials and Methods). mRNA for the ligand was detected in every tissue examined except brain (Fig 6) . The size of the predominant flt3 ligand mRNA transcript was about 1.2 kb, which is consistent with the length of the composite cDNA clone shown in Fig 2. Weaker signals for larger mRNA transcripts were also detected in several tissues, but the significance of these bands is unclear.
Generation of a soluble form of ligand by mRNA splicing. The most interesting of the alternative splices seen in the flt3 ligand cDNAs was the Al79-bp deletion in clone 14 (Fig l ) . That deletion splices out part of the extracellular domain, the transmembrane region, and about half of the cytoplasmic tail of the protein; the entire C-terminus of the protein is replaced by 26 amino acids encoded in a different reading frame. An flt3 ligand cDNA containing this deletion would be predicted to produce only a soluble form of the ligand. To test this hypothesis, the Al79-bp deletion was introduced into the full-length clone 9 cDNA, which was then transfected into CV-I/EBNA cells. The transfected cells were examined 2 days later for cell-surface expreshion of the ligand as well as for the presence of ligand activity in medium conditioned by the cells. In contrast to the Lvildtype clone, no expression of the flt3 ligand L179 \vas seen on the cell surface (Fig 7A) . consistent with the removal of the transmembrane region. Bioassay of the medium conditioned by the transfected cells showed high levels of fit3 ligand activity in both wild-type (clone 9 ) and 1179-transfected cells (Fig 7B) . Generation of a soluble form of the flt3 ligand after transfection of the full-length cDNA has now been shown for both human (this report) and murine' Rt.? ligand proteins and presumably results from proteolytic cleavage of the membrane-bound form. Some cell types may lack the putative protease responsible for ligand cleavage: thus, alternative splicing provides a second method for generating a soluble form of the ligand.
DISCUSSION
We have succeeded in isolating a human homologue of the murine flt3 ligand gene and shown that this protein is biologically active on primitive human hematopoietic cells. The human ligand is 72% identical to the murine protein at the amino acid level and conserves many of the features of the murine protein, including glycosylation sites. key cysteine residues, and splice junctions. The human ligand can bind to a soluble version of the murine fit3 receptor (data not shown) and stimulates the proliferation of BAFIBO3 cells transfected with the murine receptor (Fig S) . The murine and human flt3 ligands can each stimulate the proliferation of either murine or human cells at similar concentrations. This is in contrast to SLF, where the murine factor stimulates the proliferation of both murine and human cells, whereas the human factor acts on human cells but is 100 to 1, OOO times less active on murine cells? In the case of CSF-1, the murine factor acts only on murine cells, whereas human CSF-1 stimulates both murine and human cells." These three ligands have similar overall structures, as do the tyrosine kinase receptors to which they bind, but only flt3 ligand shows no apparent species-specific restrictions in its activity. In their extracellular domains, the mouse and human flt3 ligands are 74% identical. This value is slightly below that of the extracellular (ligand binding) domains of the mouse and human flt3 which are 83% identical. Similar analysis of the ligands and receptors for SLF and CSF-1 indicate that it is not possible to predict species specificity (ie, bioactivity of ligand on receptors of another species) by comparison of amino acid identities between mouse and human ligands and receptors (data not shown).
The murine and human flt3 ligands have different amino acids at their C-termini (Fig 3) and neither of these residues is valine. A carboxy terminal valine residue appears to be a critical determinant for extracellular cleavage of membranebound transforming growth factor a (TGFa) into a soluble growth factor." A C-terminal valine residue is also seen in SLF and CSF-l (murine or human), which are also membrane-bound proteins that generate soluble, biologically active growth factors.'.'' Although the flt3 ligand appears to have a similar overall structure to SLF and CSF-l , 5 and also generates a soluble form, it seems that either amino acids other than valine are capable of substituting for that residue to allow extracellular domain cleavage, or there is a different mechanism that leads to the generation of a soluble form of flt3 ligand. It would be of interest to determine if a C-terminal proline residue (as seen in mouse flt3 ligand) or histidine residue (human flt3 ligand) can substitute for a C-terminal valine residue to facilitate the extracellular cleavage of TGFa, SLF, or CSF-1.
Contained within the coding region of the human flt3 ligand cDNA is a stretch of five CTG triplet repeats. These repeats, located in the signal peptide, encode a stretch of five leucine residues. This type of polynucleotide triplet repeat sequence has been observed in a number of proteins.2'.22 Genetic expansion of these triplet repeats has been shown in some cases to be correlated with human disease.2',22 Polyleucine stretches encoded by triplet repeats (CTG) have been seen in the signal sequences of the so-called protective protein and in placental alkaline phosphatase," although in those particular cases no genetic diseases have been associated with the repeating sequences. It will be interesting to determine if polymorphisms exist in these repeating sequences in the human flt3 ligand and, if so, if there is an alteration in the biologic activity, expression, or intracellular localization of the ligand associated with an expansion in this region of the protein.
The widespread expression of fit3 ligand mRNA was surprising, given that only a few of a large number of cell lines screened were capable of binding a soluble version of the flt3 receptor.5 It is not clear if expression of flt3 ligand protein mirrors expression of mRNA transcripts (the mRNA may not be translated efficiently). However, the expression pattern of the ligand suggests that restrictive expression of the receptor may be the dominant factor in regulating ligandreceptor interactions. The apparent lack of flt3 ligand expression in human brain is interesting because the flt3 receptor is expressed in both fetal and adult mouse braix~.~.~ Expression of the ligand may be localized to a small region of brain that either cannot be detected at the level of Northern blot analysis or was not part of the tissue from which the RNA was isolated. In situ hybridization analysis should help to resolve this issue.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Now that the flt3 ligand has been cloned, we will be able to determine which lineages of hematopoietic cells proliferate in response to this factor, and at what stages within these lineages the cells are responsive. Data obtained thus far suggests that flt3 ligand alone induces modest proliferation and colony formation of CD34+ BM-derived progenitor cells. However, in conjunction with the hematopoietic factors IL-3, GM-CSF, or Pixy 321, synergistic effects were observed. However, unlike SLF, no effect was observed on erythroid colony formation when flt3 ligand was added with EPO, nor did SLF appear to synergize with flt3 ligand (Table  l) . Experiments are now underway to determine which subfractions of CD34+ cells are responsive to flt3 ligand.
